Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
01
Overview
SAR448289 is an investigational therapeutic candidate being developed by Sanofi for the treatment of Alzheimer's disease-related dementia. It is currently undergoing evaluation in a Phase I first-in-human clinical trial in healthy adult participants to assess its safety, tolerability, and pharmacokinetics.
Beyond the preview
Go deeper on SAR448289.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SAR448289.